Figures computed from official regulatory filings — .
Analysttarget 30 USD (+1036%) · consensus 3/5 · 0 buy · 2 hold · 0 sell
Ownershipinsiders 23.75% · institutions 2.21% · short 3.0% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Matinas BioPharma Holdings, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy. It offers MAT2501, an orally administered formulation of amikacin. The company was incorporated in 2013 and is based in Bedminster, New Jersey.
Market information source · Oct 5, 2026
SEC company identity · Oct 5, 2026
Open-market timeline · full history
28 buys— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| STERN ADAM Ktrack record | OtherD (derivative) | $220.6K | SEC |
| STERN ADAM Ktrack record | Other | $59.4K | SEC |
| STERN ADAM Ktrack record | OtherD (derivative) | $155.3 | SEC |
| STERN ADAM Ktrack record | OtherD (derivative) | $49.5K | SEC |
| STERN ADAM Ktrack record | AwardD (derivative) | $220.6K | Unusual size | SEC |
| STERN ADAM Ktrack record | OtherD (derivative) | $120.6K | SEC |
| STERN ADAM Ktrack record | Other | $120.6K | SEC |
| Sanitam Partners LLC | OtherD (derivative) | $3.1M | SEC |
| STERN ADAM Ktrack record | OtherD (derivative) | $59.4K | SEC |
| Sanitam Partners LLC | OtherD (derivative) | $823.9 | SEC |
| STERN ADAM Ktrack record | AwardD (derivative) | $120.6K | SEC |
| STERN ADAM Ktrack record | OtherD (derivative) | $515.7K | SEC |
| STERN ADAM Ktrack record | Other | $220.6K | SEC |
| Jabbour Jerome D | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| D An Evelyn | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Smith Robin Ltrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| NEUGEBOREN EDWARD | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Murphy Keith | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| EIDE ROBERT Jtrack record | BuyD (derivative) | $492K | ClusterFirst in 12mo | SEC |
| Pembroke & Partners LLC | BuyD (derivative) | n/a (No price was disclosed in the filing) | ClusterFirst in 12mo | SEC |
| Sanitam Partners LLC | BuyD (derivative) | n/a (No price was disclosed in the filing) | ClusterFirst in 12mo | SEC |
| EIDE ROBERT Jtrack record | BuyD (derivative) | n/a (No price was disclosed in the filing) | ClusterFirst in 12mo | SEC |
| Sanitam Partners LLC | BuyD (derivative) | $703K | ClusterFirst in 12mo | SEC |
| Pembroke & Partners LLC | BuyD (derivative) | $492K | ClusterFirst in 12mo | SEC |
| Matkovits Theresa | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |